4-(6-(1H-indol-5-yl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine | 1062159-44-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-(6-(1H-indol-5-yl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine
• 英文别名: 6-(1H-indol-5-yl)-4-morpholin-4-yl-1-piperidin-4-yl-1H-pyrazolo[3,4-d]pyrimidine；4-[6-(1H-indol-5-yl)-1-piperidin-4-ylpyrazolo[3,4-d]pyrimidin-4-yl]morpholine
• CAS: 1062159-44-7
• 化学式: C₂₂H₂₅N₇O
• 分子量: 403.487
• InChiKey: HBUZKDNKAOMUML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  83.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(6-(1H-indol-5-yl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine 在 水 、 乙酸乙酯 、 magnesium sulfate 作用下， 以 2-溴吡啶 为溶剂， 反应 72.0h， 以to give the title compound as a solid (30 mg, 42%)的产率得到6-(1H-indol-5-yl)-4-morpholin-4-yl-1-(1-pyridin-2-ylpiperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine
  参考文献：
  名称：

  PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS

  摘要：

  本发明涉及吡唑并嘧啶类似物，制备吡唑并嘧啶类似物的方法，包含吡唑并嘧啶类似物的组合物，以及治疗与mTOR相关疾病的方法，包括向需要治疗的受试者施用有效量的吡唑并嘧啶类似物。本发明还涉及治疗PI3K相关疾病的方法，包括向需要治疗的受试者施用有效量的吡唑并嘧啶类似物。

  公开号：

  US20080234262A1
• 作为产物：
  描述：

  3-[1-(1-benzylpiperidin-4-yl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenol 在 20% palladium hydroxide on carbon 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以55%的产率得到4-(6-(1H-indol-5-yl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine
  参考文献：
  名称：

  Discovery of Potent and Selective Inhibitors of the Mammalian Target of Rapamycin (mTOR) Kinase

  摘要：

  The mammalian target of rapamycin (mTOR) is a central regulator of cell growth, metabolism, and angiogenesis and an emerging target in cancer research. High throughput screening (HTS) of our compound collection led to the identification of 3-(4-morpholin-4-yl-1-piperidin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenol (5a), a modestly potent and nonselective inhibitor of mTOR and phosphoinositide 3-kinase (PI3K). Optimization of compound 5a, employing an mTOR homology model based on an X-ray crystal structure of closely related PI3K gamma led to the discovery of 6-(1H-indol-5-yl)-4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidine (5u), a potent and selective mTOR inhibitor (mTOR IC50 = 9 nM; PI3K alpha IC50 = 1962 nM). Compound 5u selectively inhibited cellular biomarker of mTORCl (P-S6K, P-4EBP1) and mTORC2 (P-AKT S473) over the biomarker of PI3K/PDK1 (P-AKT T308) and did not inhibit PI3K-related kinases (PIKKs) in cellular assays. These pyrazolopyrimidines represent an exciting new series of mTOR-selective inhibitors with potential for development for cancer therapy.

  DOI：

  10.1021/jm9012642

文献信息

• [EN] PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS<br/>[FR] ANALOGUES DE PYRAZOLOPYRIMIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE KINASE MTOR ET KINASE PI3
  申请人：WYETH CORP

  公开号：WO2008115974A2

  公开（公告）日：2008-09-25

  [EN] The present invention relates to Pyrazolopyrimidine Analogs, methods of making Pyrazolopyrimidine Analogs, compositions comprising a Pyrazolopyrimidine Analog, and methods for treating mTOR -related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog. The invention also relates to treating PI3K -related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog.
  [FR] La présente invention concerne des analogues de pyrazolopyrimidine, des procédés de préparation d'analogues de pyrazolopyrimidine et des compositions comprenant un analogue de pyrazolopyrimidine et des procédés de traitement de troubles liés au mTOR comprenant l'administration à un sujet qui en a besoin d'une quantité efficace d'un analogue de pyrazolopyrimidine. L'invention concerne également le traitement de troubles liés au PI3K comprenant l'administration à un sujet qui en a besoin d'une quantité efficace d'un analogue de pyrazolopyrimidine.